# EDGAR Filing Document

**Accession Number:** 0000728387
**File Stem:** 0001193125-26-249594
**Filing Date:** 2026-6
**Character Count:** 9789
**Document Hash:** 6add471d3a2771cb861c26f585373582
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-249594.hdr.sgml**: 20260601

**ACCESSION NUMBER**: 0001193125-26-249594

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 66

**CONFORMED PERIOD OF REPORT**: 20260601

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260601

**DATE AS OF CHANGE**: 20260601

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Perspective Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000728387
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411458152
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33407
- **FILM NUMBER:** 261047029

**BUSINESS ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121
- **BUSINESS PHONE:** 206-676-0900

**MAIL ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Isoray, Inc.
- **DATE OF NAME CHANGE:** 20181231

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IsoRay, Inc.
- **DATE OF NAME CHANGE:** 20050805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CENTURY PARK PICTURES CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 01, 2026<br>

------

Perspective Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-33407 | 41-1458152 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| c/o Perspective Therapeutics, Inc.<br>2401 Elliott Avenue<br>Suite 320 |  |  |
| Seattle**,** Washington |  | 98121 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (206) 676-0900<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.001 par value | CATX | NYSE American LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 8.01 Other Events.
On June 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 99.1 | [<u>Corporate Presentation</u>](catx-ex99_1.htm). |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **PERSPECTIVE THERAPEUTICS, INC.** |
| Date: | June 1, 2026 | By:  | /s/ Joel Sendek |
|  |  |  | Joel Sendek<br>Chief Financial Officer |

---

------

## Exhibit 99.1

![Slide 1](catx-ex99_1s1.jpg)

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

------

![Slide 2](catx-ex99_1s2.jpg)

------

![Slide 3](catx-ex99_1s3.jpg)

Engineering the Alpha Advantage in Targeted Oncology

------

![Slide 4](catx-ex99_1s4.jpg)

Unlocking New Treatment Options Across Solid Tumors:

------

![Slide 5](catx-ex99_1s5.jpg)

Optimizing the Entire System

------

![Slide 6](catx-ex99_1s6.jpg)

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

------

![Slide 7](catx-ex99_1s7.jpg)

Optimizing Structural Chemistry:

------

![Slide 8](catx-ex99_1s8.jpg)

Choosing The Right Isotope

------

![Slide 9](catx-ex99_1s9.jpg)

Not All ²¹²Pb Programs Are Created Equal

------

![Slide 10](catx-ex99_1s10.jpg)

------

![Slide 11](catx-ex99_1s11.jpg)

Advancing a Theranostic Approach:

------

![Slide 12](catx-ex99_1s12.jpg)

Solid Tumors are an Attractive Market for Radiopharmaceuticals

------

![Slide 13](catx-ex99_1s13.jpg)

Expanding the Addressable Market

------

![Slide 14](catx-ex99_1s14.jpg)

Direct-to-Hospital Delivery through Integrated Isotope Production

------

![Slide 15](catx-ex99_1s15.jpg)

Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product

------

![Slide 16](catx-ex99_1s16.jpg)

Reaching the Largest Addressable Market with Regional Manufacturing

------

![Slide 17](catx-ex99_1s17.jpg)

Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio

------

![Slide 18](catx-ex99_1s18.jpg)

SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

------

![Slide 19](catx-ex99_1s19.jpg)

VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

------

![Slide 20](catx-ex99_1s20.jpg)

Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs

------

![Slide 21](catx-ex99_1s21.jpg)

VMT-⍺-NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis

------

![Slide 22](catx-ex99_1s22.jpg)

Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO 2026 Data Analysis

------

![Slide 23](catx-ex99_1s23.jpg)

VMT-α-NET Responses Deepen Over Time

------

![Slide 24](catx-ex99_1s24.jpg)

VMT-⍺-NET: Durable Disease Control Across All Doses

------

![Slide 25](catx-ex99_1s25.jpg)

Spider Plot of Tumor Change Over Time by Patient

------

![Slide 26](catx-ex99_1s26.jpg)

Best-in-class Safety Profile1

------

![Slide 27](catx-ex99_1s27.jpg)

Blood Creatinine During Follow-up for All Patients Treated (n=68)

------

![Slide 28](catx-ex99_1s28.jpg)

VMT-α-NET's Compelling Profile Supports Potential Registration Study at Current Dose Level

------

![Slide 29](catx-ex99_1s29.jpg)

Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

------

![Slide 30](catx-ex99_1s30.jpg)

VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

------

![Slide 31](catx-ex99_1s31.jpg)

Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

------

![Slide 32](catx-ex99_1s32.jpg)

Preliminary Anti-tumor Activity Observed at 3.0 mCi Dose of VMT01

------

![Slide 33](catx-ex99_1s33.jpg)

Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 10% of Patients)

------

![Slide 34](catx-ex99_1s34.jpg)

VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development

------

![Slide 35](catx-ex99_1s35.jpg)

FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

------

![Slide 36](catx-ex99_1s36.jpg)

PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

------

![Slide 37](catx-ex99_1s37.jpg)

Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

------

![Slide 38](catx-ex99_1s38.jpg)

PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

------

![Slide 39](catx-ex99_1s39.jpg)

Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

------

![Slide 40](catx-ex99_1s40.jpg)

------

![Slide 41](catx-ex99_1s41.jpg)

A Decade of Deliberate, End-to-End Engineering

------

![Slide 42](catx-ex99_1s42.jpg)

Built Over a Decade:

------

![Slide 43](catx-ex99_1s43.jpg)

------

![Slide 44](catx-ex99_1s44.jpg)

Abbreviations

------

![Slide 45](catx-ex99_1s45.jpg)

APPENDIX

------

![Slide 46](catx-ex99_1s46.jpg)

------

![Slide 47](catx-ex99_1s47.jpg)

NETs Trials

------

![Slide 48](catx-ex99_1s48.jpg)

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

------

![Slide 49](catx-ex99_1s49.jpg)

Refractory Metastatic Melanoma Trials

------

![Slide 50](catx-ex99_1s50.jpg)

ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma

------

![Slide 51](catx-ex99_1s51.jpg)

------

![Slide 52](catx-ex99_1s52.jpg)

------

![Slide 53](catx-ex99_1s53.jpg)

Construct designed for better clinical outcome

------

![Slide 54](catx-ex99_1s54.jpg)

212Pb Uniquely Suited for Combination with Immune Check Point Inhibitors

------

![Slide 55](catx-ex99_1s55.jpg)

------

![Slide 56](catx-ex99_1s56.jpg)